Cytokinetics(US:CYTK) Benzinga·2025-12-16 21:00Core Viewpoint - Cytokinetics granted stock options and restricted stock units (RSUs) to new employees as an inducement for their employment, reflecting the company's strategy to attract talent in the biopharmaceutical sector [1][3]. Summary by Sections Stock Options and RSUs - On December 15, 2025, Cytokinetics granted stock options to purchase 21,399 shares and 14,422 RSUs to 10 new employees [1]. - The RSUs will vest over 3 years, with 40% vesting on the first anniversary, another 40% on the second anniversary, and the final 20% on the third anniversary, contingent on continued employment [2]. - The stock options have an exercise price of $62.16 per share, equal to the closing price on the grant date, and will vest over 4 years, with 1/4th vesting on the first anniversary and the remainder vesting monthly over the next 36 months [2]. Company Overview - Cytokinetics is a specialty cardiovascular biopharmaceutical company with over 25 years of experience in muscle biology, focusing on developing new medicines for cardiac muscle dysfunction [4]. - The company is preparing for potential regulatory approvals and commercialization of aficamten, a cardiac myosin inhibitor, following positive Phase 3 trial results for obstructive hypertrophic cardiomyopathy [4]. - Other products in development include omecamtiv mecarbil for heart failure with severely reduced ejection fraction, ulacamten for heart failure with preserved ejection fraction, and CK-089 for muscular dystrophy and other muscle function impairments [4].